Developer docs
API playgroundTry for free, no card

Search company profiles

Elucid

Full company profile

uuid00007ha

Namestring
Elucid
Legal namestring
Elucid Bioimaging Inc.
Websiteurl
elucid.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Elucid is a Boston-based AI medical technology company that develops PlaqueIQ, an FDA-cleared and CE-marked software platform that performs non-invasive analysis of coronary and carotid CT angiography (CTA) scans to quantify and classify atherosclerotic plaque. The core technology, branded CT Virtual Histology (CT-VH), uses proprietary algorithms trained and validated against tens of thousands of histopathologic tissue annotations from CVPath Institute, enabling differentiation of lipid-rich necrotic core (LRNC), calcified plaque, and non-calcified plaque with histology-level correlation (r=0.99 total plaque; r=0.88 LRNC). The product is delivered to physicians as a DICOM-wrapped PDF to PACS and an interactive browser interface, with a Lesion Inspection Tool enabling lesion-level analysis.

Elucid generates revenue by licensing PlaqueIQ to hospitals, imaging centers, and physician practices on a per-scan basis, with payment tied to reimbursement codes including CPT 75577 (effective January 2026 at a $1,012 national average) and Category III codes 0710T-0713T for LRNC quantification. Coverage now extends to over 70% of insured Americans through five of seven Medicare Administrative Contractors and major commercial payors (Aetna, Humana, Cigna, UnitedHealthcare). Go-to-market is enterprise field sales targeting hospitals, health systems, imaging centers, and clinical research institutions, supported by conference presence (SCCT, AHA, ACC), KOL engagement, and reimbursement support programs.

The company has raised approximately $157M cumulatively across multiple rounds including an $80M Series C led by Elevage Medical Technologies in November 2023, with an additional financing disclosed in October 2025. Operating geographies span the United States, United Kingdom, European Union, and South Korea. Plaque-Derived FFRCT, currently under development, is positioned to extend the platform into non-invasive fractional flow reserve measurement once FDA-cleared.

Short descriptiontext

Elucid is a Boston-based AI medical technology company whose PlaqueIQ software performs FDA-cleared, histology-validated non-invasive analysis of coronary and carotid CT angiography to quantify atherosclerotic plaque for hospitals, imaging centers, and physician practices.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular imaging software, AI plaque analysis, CT angiography diagnostics, non-invasive histology imaging, atherosclerosis quantification
Industry1 code
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiovascular Imaging Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1PlaqueIQ Software Licensing
TypeSubscription Recurring
Description

Elucid generates revenue through licensing its PlaqueIQ software to hospitals, imaging centers, and physician practices. The software is used in conjunction with coronary CT angiography (CCTA) scans. Revenue is tied to reimbursement codes including Category I CPT code 75577 effective January 2026.

elucid.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Coronary plaque analysis reimbursement for imaging centers and physician offices
ModelOtherBilling cadencePay-as-you-go
Notes

Category I CPT code 75577 with national average payment of $1,012 for imaging centers and physician offices. 2026 OPPS rate of $951 for hospital outpatient settings.

elucid.com
2Hospital outpatient cardiac CT angiography
ModelOtherBilling cadencePay-as-you-go
Notes

CMS rule effective January 1, 2025 doubled CCTA reimbursement from $175 to $357.13 for hospitals and outpatient clinics.

elucid.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1PlaqueIQ
Description

AI-powered image analysis software for quantification and classification of coronary and carotid plaque morphology, validated against ground truth histology. The only FDA-cleared non-invasive plaque analysis based on objective histology.

elucid.com
+2 more records
Core offering1 text field

Elucid develops and licenses PlaqueIQ, an FDA-cleared and CE-marked AI-powered image analysis software that performs non-invasive quantification and classification of atherosclerotic plaque morphology from coronary and carotid CT angiography scans, validated against ground-truth histology. The software delivers 3D vessel visualization, plaque component quantification (lipid-rich necrotic core, calcified, non-calcified), and lesion-level analysis tools to hospitals, imaging centers, and physician practices for cardiovascular disease risk assessment and treatment planning.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Correlation with histology: Total Plaque r=0.99, Calcified r=0.95, Non-Calcified r=0.86, LRNC r=0.88
+2 more records
Product overview1 text field

Elucid is a Boston-based AI medical technology company offering a unified product ecosystem centered on Plaque-IQ, its flagship FDA-cleared and CE-marked AI-powered plaque analysis software. Plaque-IQ provides non-invasive CT angiography (CTA)-based plaque quantification and classification (including lipid-rich necrotic core) validated against ground-truth histology, available for both coronary and carotid arteries. A Lesion Inspection Tool within the Plaque-IQ suite adds lesion-level analysis capability. Elucid's investigational FFRCT product is derived from the Plaque-IQ algorithm, uniquely providing plaque concordance between plaque measurements and FFRCT values, pending FDA clearance. The company also offers clinical research services leveraging its CTA analysis platform. Plaque-IQ results are delivered as DICOM-wrapped PDFs to PACS and interactive browser-based reports.

Product and service4 records
1PlaqueIQ Image Analysis Software
CategoryCardiovascular Imaging Software
Description

FDA-cleared and CE-marked AI-powered image analysis software for non-invasive quantification and classification of atherosclerotic plaque morphology from CT angiography (CTA) scans. Validated against ground-truth histology, it classifies plaque into calcified, non-calcified, and lipid-rich necrotic core (LRNC) components, delivering 3D vessel visualization and actionable reports to PACS. Available for both coronary and carotid arteries.

2PlaqueIQ Image Analysis Software for the Carotid Arteries
CategoryCardiovascular Imaging Software
Description

Carotid artery extension of the PlaqueIQ platform, the first and only CT-based plaque analysis software indicated for carotid anatomy. Enables physicians to quantify and classify plaque morphology in carotid arteries to assess risk of rupture and ischemic stroke, identifying lipid-rich necrotic core as a marker of cerebrovascular risk.

3Lesion Inspection Tool
CategoryCardiovascular Imaging Software
Description

Lesion-level plaque composition analysis tool within the Plaque-IQ software suite that enables physicians to interrogate any specific lesion or region and access quantitative results for that segment, including lipid-rich necrotic core quantification at the individual lesion level.

4Elucid Clinical Research Services
CategoryClinical Research Services
Description

CTA analysis capabilities offered for clinical research applications including events tracking, pharmaceutical research, and investigator-initiated studies. Supports academic medical centers and research institutions conducting cardiovascular clinical research through a formal application process.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Dr. Richard E. Kuntz, MD, MSc
Strategic tierCoreTypeOthersAnnounced on2025-07-17
Description

Former senior VP and chief medical/scientific officer of Medtronic, founder and CSO of Harvard Clinical Research Institute, and interventional cardiologist at Brigham and Women's Hospital. Provides clinical trial strategy and product innovation guidance.

elucid.com
2Dr. Shamiram Feinglass, MD, MPH
Strategic tierCoreTypeOthersAnnounced on2025-07-17
Description

Managing director at Manatt Health with expertise in market access, policy making, and regulatory strategy. Former executive at Danaher and Zimmer-Biomet, former regulator at CMS.

elucid.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-18
Description

Partnership with world-renowned cardiovascular pathologists at CVPath Institute for ground-truth histology validation. Dr. Renu Virmani serves as President & Medical Director and has validated Elucid's algorithms as highly accurate for tissue characterization compared to ex vivo histopathology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-18
Description

Lead investigator for the PRE-VUE CCT Registry Study, an international multicenter trial evaluating PlaqueIQ's prognostic accuracy in predicting major cardiac adverse events.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-18
Description

Lead investigator for the PRE-VUE CCT Registry Study assessing PlaqueIQ and investigational FFRCT software in patients with clinically indicated CCTA.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in cardiac CT-based diagnostics. HeartFlow pioneered FFRCT (HeartFlow Analysis) for non-invasive assessment of coronary blockages and is the incumbent in CT-derived cardiac physiology assessment; Elucid's Plaque-Derived FFRCT directly targets this category with the addition of plaque concordance.

TypeDirect peer
Description

Closest direct competitor in AI-powered CCTA plaque analysis. Cleerly offers software that quantifies and characterizes coronary plaque from CCTA scans, addressing the same cardiologist customer base with similar lesion-level plaque composition analysis.

TypeBroad incumbent
Description

Major incumbent in cardiac CT imaging, scanners (Revolution CT), and AI-enabled post-processing (AI-Rad Companion). Comparable as the dominant OEM whose installed scanner base is the source of CCTA images that PlaqueIQ analyzes; overlapping capabilities in AI plaque characterization.

TypeBroad incumbent
Description

Major incumbent in cardiac imaging (IQon Spectral CT, IntelliSpace Portal) and acquired Volcano Corporation (where Chairman Huennekens was previously CEO). Comparable as a broad imaging vendor with overlapping AI image analysis portfolio and direct cardiology channel.

TypeBroad incumbent
Description

Major incumbent in cardiac CT (Force, NAEOTOM Alpha), post-processing software (syngo.via), and AI-augmented imaging. Comparable as the dominant OEM whose scanners produce CCTA images consumed by PlaqueIQ and which is building native AI plaque analytics.

TypeDirect peer
Description

Specialized cardiac imaging post-processing software vendor (cvi42) used by cardiologists and radiologists for CT and MR cardiac analysis. Comparable as a focused cardiac imaging software platform with similar customer workflows in advanced cardiac imaging.

TypeEmerging player
Description

Cloud-native AI medical imaging platform with FDA-cleared cardiac MRI and CT applications. Comparable as an AI imaging specialist addressing similar cardiology use cases with a SaaS delivery model.

TypeEmerging player
Description

AI medical imaging company with broad radiology AI suite deployed in hospital workflows. Comparable as an enterprise imaging AI vendor competing for the same hospital IT budgets and clinical workflow integration slots.

TypeEmerging player
Description

AI medical imaging company focused on time-sensitive conditions (stroke, cardiology). Comparable as a specialty clinical AI workflow vendor with hospital enterprise sales motion and reimbursement-driven business model.

TypeBroad incumbent
Description

Major incumbent in cardiac CT scanners (Aquilion ONE) and Vitrea post-processing workstation with AI features. Comparable as a scanner OEM whose installed base produces CCTA images and which is embedding native plaque analysis capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elucid

Cardiovascular Imaging Softwareelucid.com

Elucid is a Boston-based AI medical technology company whose PlaqueIQ software performs FDA-cleared, histology-validated non-invasive analysis of coronary and carotid CT angiography to quantify atherosclerotic plaque for hospitals, imaging centers, and physician practices.

What Elucid does

Elucid is a Boston-based AI medical technology company that develops PlaqueIQ, an FDA-cleared and CE-marked software platform that performs non-invasive analysis of coronary and carotid CT angiography (CTA) scans to quantify and classify atherosclerotic plaque. The core technology, branded CT Virtual Histology (CT-VH), uses proprietary algorithms trained and validated against tens of thousands of histopathologic tissue annotations from CVPath Institute, enabling differentiation of lipid-rich necrotic core (LRNC), calcified plaque, and non-calcified plaque with histology-level correlation (r=0.99 total plaque; r=0.88 LRNC). The product is delivered to physicians as a DICOM-wrapped PDF to PACS and an interactive browser interface, with a Lesion Inspection Tool enabling lesion-level analysis.

Elucid generates revenue by licensing PlaqueIQ to hospitals, imaging centers, and physician practices on a per-scan basis, with payment tied to reimbursement codes including CPT 75577 (effective January 2026 at a $1,012 national average) and Category III codes 0710T-0713T for LRNC quantification. Coverage now extends to over 70% of insured Americans through five of seven Medicare Administrative Contractors and major commercial payors (Aetna, Humana, Cigna, UnitedHealthcare). Go-to-market is enterprise field sales targeting hospitals, health systems, imaging centers, and clinical research institutions, supported by conference presence (SCCT, AHA, ACC), KOL engagement, and reimbursement support programs.

The company has raised approximately $157M cumulatively across multiple rounds including an $80M Series C led by Elevage Medical Technologies in November 2023, with an additional financing disclosed in October 2025. Operating geographies span the United States, United Kingdom, European Union, and South Korea. Plaque-Derived FFRCT, currently under development, is positioned to extend the platform into non-invasive fractional flow reserve measurement once FDA-cleared.

Elucid firmographics

Firmographics
Name
Elucid
Legal name
Elucid Bioimaging Inc.
Website
https://elucid.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Elucid is a Boston-based AI medical technology company whose PlaqueIQ software performs FDA-cleared, histology-validated non-invasive analysis of coronary and carotid CT angiography to quantify atherosclerotic plaque for hospitals, imaging centers, and physician practices.
Ownership category
akta.pro rank

Elucid industry classification

Industry
Product category
Cardiovascular Imaging Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiovascular imaging software
  • AI plaque analysis
  • CT angiography diagnostics
  • Non-invasive histology imaging
  • Atherosclerosis quantification

Where Elucid is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Elucid business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. PlaqueIQ Software Licensing: Elucid generates revenue through licensing its PlaqueIQ software to hospitals, imaging centers, and physician practices. The software is used in conjunction with coronary CT angiography (CCTA) scans. Revenue is tied to reimbursement codes including Category I CPT code 75577 effective January 2026.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCoronary plaque analysis reimbursement for imaging centers and physician offices
OtherPay-as-you-goHospital outpatient cardiac CT angiography

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Elucid product offering

Product offering

Core offering

Elucid develops and licenses PlaqueIQ, an FDA-cleared and CE-marked AI-powered image analysis software that performs non-invasive quantification and classification of atherosclerotic plaque morphology from coronary and carotid CT angiography scans, validated against ground-truth histology. The software delivers 3D vessel visualization, plaque component quantification (lipid-rich necrotic core, calcified, non-calcified), and lesion-level analysis tools to hospitals, imaging centers, and physician practices for cardiovascular disease risk assessment and treatment planning.

Product overview

Elucid is a Boston-based AI medical technology company offering a unified product ecosystem centered on Plaque-IQ, its flagship FDA-cleared and CE-marked AI-powered plaque analysis software. Plaque-IQ provides non-invasive CT angiography (CTA)-based plaque quantification and classification (including lipid-rich necrotic core) validated against ground-truth histology, available for both coronary and carotid arteries. A Lesion Inspection Tool within the Plaque-IQ suite adds lesion-level analysis capability. Elucid's investigational FFRCT product is derived from the Plaque-IQ algorithm, uniquely providing plaque concordance between plaque measurements and FFRCT values, pending FDA clearance. The company also offers clinical research services leveraging its CTA analysis platform. Plaque-IQ results are delivered as DICOM-wrapped PDFs to PACS and interactive browser-based reports.

Differentiator

Problem solved

Functional benefit

Brands

  • PlaqueIQ: AI-powered image analysis software for quantification and classification of coronary and carotid plaque morphology, validated against ground truth histology. The only FDA-cleared non-invasive plaque analysis based on objective histology.
  • Plaque-Derived FFRCT
  • CT Virtual Histology (CT-VH)

Products and services

  • PlaqueIQ Image Analysis Software FDA-cleared and CE-marked AI-powered image analysis software for non-invasive quantification and classification of atherosclerotic plaque morphology from CT angiography (CTA) scans. Validated against ground-truth histology, it classifies plaque into calcified, non-calcified, and lipid-rich necrotic core (LRNC) components, delivering 3D vessel visualization and actionable reports to PACS. Available for both coronary and carotid arteries.
  • PlaqueIQ Image Analysis Software for the Carotid Arteries Carotid artery extension of the PlaqueIQ platform, the first and only CT-based plaque analysis software indicated for carotid anatomy. Enables physicians to quantify and classify plaque morphology in carotid arteries to assess risk of rupture and ischemic stroke, identifying lipid-rich necrotic core as a marker of cerebrovascular risk.
  • Lesion Inspection Tool Lesion-level plaque composition analysis tool within the Plaque-IQ software suite that enables physicians to interrogate any specific lesion or region and access quantitative results for that segment, including lipid-rich necrotic core quantification at the individual lesion level.
  • Elucid Clinical Research Services CTA analysis capabilities offered for clinical research applications including events tracking, pharmaceutical research, and investigator-initiated studies. Supports academic medical centers and research institutions conducting cardiovascular clinical research through a formal application process.

Quantifiable outcome

  • Correlation with histology: Total Plaque r=0.99, Calcified r=0.95, Non-Calcified r=0.86, LRNC r=0.88
  • +2 more outcomes

Companies that use Elucid

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Elucid technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Elucid partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Dr. Richard E. Kuntz, MD, MSccoreOthers · 17 July 2025Former senior VP and chief medical/scientific officer of Medtronic, founder and CSO of Harvard Clinical Research Institute, and interventional cardiologist at Brigham and Women's Hospital. Provides clinical trial strategy and product innovation guidance.
  • Dr. Shamiram Feinglass, MD, MPHcoreOthers · 17 July 2025Managing director at Manatt Health with expertise in market access, policy making, and regulatory strategy. Former executive at Danaher and Zimmer-Biomet, former regulator at CMS.
  • CVPath InstitutecoreStrategic or Co-development Partner · 18 July 2024Partnership with world-renowned cardiovascular pathologists at CVPath Institute for ground-truth histology validation. Dr. Renu Virmani serves as President & Medical Director and has validated Elucid's algorithms as highly accurate for tissue characterization compared to ex vivo histopathology.
  • Emory University / Dr. Carlo De CeccocoreStrategic or Co-development Partner · 18 July 2024Lead investigator for the PRE-VUE CCT Registry Study, an international multicenter trial evaluating PlaqueIQ's prognostic accuracy in predicting major cardiac adverse events.
  • Gottsegen National Cardiovascular Center / Dr. Márton KolossvárycoreStrategic or Co-development Partner · 18 July 2024Lead investigator for the PRE-VUE CCT Registry Study assessing PlaqueIQ and investigational FFRCT software in patients with clinically indicated CCTA.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Elucid competitors and assessment

Company assessment

Direct peers

  • HeartFlow: Direct competitor in cardiac CT-based diagnostics. HeartFlow pioneered FFRCT (HeartFlow Analysis) for non-invasive assessment of coronary blockages and is the incumbent in CT-derived cardiac physiology assessment; Elucid's Plaque-Derived FFRCT directly targets this category with the addition of plaque concordance.
  • Cleerly: Closest direct competitor in AI-powered CCTA plaque analysis. Cleerly offers software that quantifies and characterizes coronary plaque from CCTA scans, addressing the same cardiologist customer base with similar lesion-level plaque composition analysis.
  • Circle Cardiovascular Imaging: Specialized cardiac imaging post-processing software vendor (cvi42) used by cardiologists and radiologists for CT and MR cardiac analysis. Comparable as a focused cardiac imaging software platform with similar customer workflows in advanced cardiac imaging.

Broad incumbents

  • GE HealthCare: Major incumbent in cardiac CT imaging, scanners (Revolution CT), and AI-enabled post-processing (AI-Rad Companion). Comparable as the dominant OEM whose installed scanner base is the source of CCTA images that PlaqueIQ analyzes; overlapping capabilities in AI plaque characterization.
  • Philips: Major incumbent in cardiac imaging (IQon Spectral CT, IntelliSpace Portal) and acquired Volcano Corporation (where Chairman Huennekens was previously CEO). Comparable as a broad imaging vendor with overlapping AI image analysis portfolio and direct cardiology channel.
  • Siemens Healthineers: Major incumbent in cardiac CT (Force, NAEOTOM Alpha), post-processing software (syngo.via), and AI-augmented imaging. Comparable as the dominant OEM whose scanners produce CCTA images consumed by PlaqueIQ and which is building native AI plaque analytics.
  • Canon Medical Systems: Major incumbent in cardiac CT scanners (Aquilion ONE) and Vitrea post-processing workstation with AI features. Comparable as a scanner OEM whose installed base produces CCTA images and which is embedding native plaque analysis capabilities.

Emerging players

  • Arterys: Cloud-native AI medical imaging platform with FDA-cleared cardiac MRI and CT applications. Comparable as an AI imaging specialist addressing similar cardiology use cases with a SaaS delivery model.
  • Aidoc: AI medical imaging company with broad radiology AI suite deployed in hospital workflows. Comparable as an enterprise imaging AI vendor competing for the same hospital IT budgets and clinical workflow integration slots.
  • Viz.ai: AI medical imaging company focused on time-sensitive conditions (stroke, cardiology). Comparable as a specialty clinical AI workflow vendor with hospital enterprise sales motion and reimbursement-driven business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Elucid social profiles

Digital presence

Elucid compliance and trust

Trust signal

Compliance3 records

Elucid financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elucid leadership team

Management profile

Number of profiles

Profiles13 records

Elucid funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elucid M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elucid

What does Elucid do?

Elucid develops and licenses PlaqueIQ, an FDA-cleared and CE-marked AI-powered image analysis software that performs non-invasive quantification and classification of atherosclerotic plaque morphology from coronary and carotid CT angiography scans, validated against ground-truth histology. The software delivers 3D vessel visualization, plaque component quantification (lipid-rich necrotic core, calcified, non-calcified), and lesion-level analysis tools to hospitals, imaging centers, and physician practices for cardiovascular disease risk assessment and treatment planning.

Is Elucid a public or private company?

Elucid is a private company. It is classified as venture growth investor backed and is currently operating.

When was Elucid founded?

Elucid was founded in 2017. It employs 101 to 250 people.

Where is Elucid based?

Elucid is headquartered in Boston, United States, in the North America region.

How does Elucid make money?

One revenue line is on record: plaqueIQ Software Licensing.

Who are Elucid's main competitors?

Direct peers on record are HeartFlow, Cleerly and Circle Cardiovascular Imaging. Broad incumbents are GE HealthCare, Philips, Siemens Healthineers and Canon Medical Systems. Emerging players are Arterys, Aidoc and Viz.ai.

Does Elucid have an API?

No public API is recorded for Elucid.

What industry is Elucid in?

Elucid's product category is Cardiovascular Imaging Software. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SdbnELUCIDATE Study Demonstrates 93 Percent Accuracy with Strong Performance in the “Gray Zone” for Elucid’s FDA-cleared FFR-IQ™ – San Diego Biotechnology NetworkElucid presented ELUCIDATE study results at TCT 2026, showing 92.9% vessel-level diagnostic accuracy for its FFR-IQ software versus invasive fractional flow reserve. The study supported the FDA 510(k) clearance of the software.Business Wire BlogELUCIDATE Study Demonstrates 93 Percent Accuracy with Strong Performance in the “Gray Zone” for Elucid’s FDA-cleared FFR-IQ™Elucid presented ELUCIDATE study results at TCT 2026, showing 92.9% vessel-level diagnostic accuracy for its FDA-cleared FFR-IQ software versus invasive FFR. The study also reported 84.1% accuracy in the gray zone (FFR 0.75-0.85) and 92.2% sensitivity and 93.1% specificity.FinancialContent Business PageELUCIDATE Study Demonstrates 93 Percent Accuracy with Strong Performance in the “Gray Zone” for Elucid’s FDA-cleared FFR-IQ™Elucid presented ELUCIDATE study results at TCT 2026, showing 92.9% vessel-level diagnostic accuracy for its FDA-cleared FFR-IQ software versus invasive FFR. The study also reported 84.1% accuracy in the gray zone (FFR 0.75-0.85) and 92.2% sensitivity and 93.1% specificity.HIT ConsultantElucid Scores FDA Clearance for FFR-IQ to Unify Plaque Biology and HemodynamicsElucid received FDA 510(k) clearance for FFR-IQ, software estimating fractional flow reserve from CCTA. The clearance is based on a trial of 491 vessels across 347 patients, showing 92.2% sensitivity and 93.1% specificity. The platform integrates plaque analysis to guide cath lab triage and disease management.Business Wire BlogElucid Announces FDA Clearance of FFR-IQ™ and Commercial Availability of the Most Accurate¹ FFR-CT SoftwareElucid announced FDA 510(k) clearance of FFR-IQ, its AI-powered FFR-CT software, with BioIntegrated FFR-CT incorporating coronary anatomy and plaque composition. The ELUCIDATE FFR-CT study showed 92.2% sensitivity and 93.1% specificity, the highest among FFR-CT validation studies. Results will be presented at TCT in San Diego on November 1.FinancialContent Business PageElucid Announces FDA Clearance of FFR-IQ™ and Commercial Availability of the Most Accurate¹ FFR-CT SoftwareElucid announced FDA 510(k) clearance of FFR-IQ, its software for noninvasive coronary physiology estimation from CT angiography. The ELUCIDATE FFR-CT study showed 92.2% sensitivity and 93.1% specificity, the highest among FFR-CT validation studies. Results will be presented at TCT in San Diego on November 1.Medical BuyerElucid names Mark Miller as CROElucid appointed Mark Miller as chief revenue officer, reporting to CEO Kelly Huang. Miller brings over 25 years of sales experience in cardiovascular imaging and AI, and will lead the commercial launch of its cardiovascular platform pending FDA clearance of BioIntegrated FFR-CT software.BostonGlobe.comAI agents like Muse run into pushback from Amazon, InsurifyAmazon and Insurify have blocked Meta's Muse AI agent, citing terms-of-service violations and risks like credit checks. Insurify's CEO said the bot made mistakes and clicked ads, while Amazon barred it for posing as a human shopper. Other vendors like Wayfair and Toast have welcomed the bot.Business Wire BlogElucid Appoints Mark Miller as Chief Revenue Officer to Lead Commercial Expansion Ahead of BioIntegrated FFR-CT LaunchElucid appointed Mark Miller as chief revenue officer to lead commercial expansion ahead of its BioIntegrated FFR-CT software launch. Miller brings over 25 years of cardiovascular imaging sales experience and will report to CEO Kelly Huang. The company is pursuing FDA clearance for the FFR-CT software, pending approval.FinancialContent Business PageElucid Appoints Mark Miller as Chief Revenue Officer to Lead Commercial Expansion Ahead of BioIntegrated FFR-CT LaunchElucid appointed Mark Miller as chief revenue officer to lead commercial expansion ahead of its BioIntegrated FFR-CT software launch. The company's Plaque-IQ is FDA-cleared, while FFR-CT is pending FDA clearance. Miller brings over 25 years of cardiovascular imaging sales experience.